In CRC, inhibition of NETs with DNase I results in the reversal of anti-PD-1 blockade resistance [63]; thus, exploring the relationship between NETs and adaptive immunity may provide novel ideas for tumor therapy. Here, DNASE1 is linked to neoplasm.